WO2011156900A3 - Compounds, compositions and methods for treatment of multiple sclerosis - Google Patents

Compounds, compositions and methods for treatment of multiple sclerosis Download PDF

Info

Publication number
WO2011156900A3
WO2011156900A3 PCT/CA2011/000694 CA2011000694W WO2011156900A3 WO 2011156900 A3 WO2011156900 A3 WO 2011156900A3 CA 2011000694 W CA2011000694 W CA 2011000694W WO 2011156900 A3 WO2011156900 A3 WO 2011156900A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
multiple sclerosis
compositions
treatment
Prior art date
Application number
PCT/CA2011/000694
Other languages
French (fr)
Other versions
WO2011156900A2 (en
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc. filed Critical Waratah Pharmaceuticals Inc.
Publication of WO2011156900A2 publication Critical patent/WO2011156900A2/en
Publication of WO2011156900A3 publication Critical patent/WO2011156900A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds, compositions dosage forms and methods comprising 6-phenyl-4-pyridin-4-yl-3-(4-pyrimidin-2-yl-piperazin-1-yl)-pyridazine hydrochloride or a pharmaceutically acceptable salt thereof, and methods for treating multiple sclerosis in a subject using same.
PCT/CA2011/000694 2010-06-17 2011-06-16 Compounds, compositions and methods for treatment of multiple sclerosis WO2011156900A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35578910P 2010-06-17 2010-06-17
US61/355,789 2010-06-17

Publications (2)

Publication Number Publication Date
WO2011156900A2 WO2011156900A2 (en) 2011-12-22
WO2011156900A3 true WO2011156900A3 (en) 2012-02-09

Family

ID=45348589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/000694 WO2011156900A2 (en) 2010-06-17 2011-06-16 Compounds, compositions and methods for treatment of multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2011156900A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202019425A (en) * 2018-07-20 2020-06-01 德商馬克專利公司 Methods for treatment and prevention of multiple sclerosis using substituted amino-pyrimidine compounds
WO2023163951A1 (en) * 2022-02-23 2023-08-31 Immunochem Therapeutics, Llc Treatment of intracranial hemorrhage

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain

Also Published As

Publication number Publication date
WO2011156900A2 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2012062925A3 (en) Compounds and methods for treating pain
UA108087C2 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptane-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2012002688A3 (en) Methods of treating restless legs syndrome
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
IN2014KN00948A (en)
EP2883875A4 (en) N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011055944A3 (en) Methods for treating fibromyalgia syndrome
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
MX2014008020A (en) Phenyl carbamate compounds for use in preventing or treating epilesy.
WO2012002687A3 (en) Methods for treating bipolar disorder
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EA201691759A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY HYPERTENSION
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
GEP201706656B (en) 2-thiopyrimidinones
WO2013098416A3 (en) Pain relief compounds
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2012017321A3 (en) Treatment for dyslipidemia
JO3145B1 (en) Compounds useful for inhibiting chk1
EP3406242B8 (en) Tlr4 antagonist for use in the treatment of increased ammonia plasma levels

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11794985

Country of ref document: EP

Kind code of ref document: A2